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journal homepage: www.elsevier.com/locate/ihjAcute coronary syndromes (ACS) are the most important
manifestation of CAD, both due to their high incidence and the
associated high mortality and morbidity. ACS has been
extensively studied in the western world and almost all the
therapies that are used in the contemporary treatment of ACS
were developed and validated in North America and Europe
and have been studied in a limited fashion in the Indian
context. While it is unlikely that the pathophysiology of plaque
instability and the resultant atherothrombosis differ across
the globe in an average patient, the care and outcome of
patients with any illness are strongly impacted by local
cultural, economic, and societal norms. This makes it vital that
we continuously examine the treatment and outcome of
common conditions such as ACS in the Indian context to
deﬁne how their epidemiology is evolving and to guide
development of impactful interventions.
The current issue of the journal carries two articles on ACS
and both highlight noteworthy achievements and identify
important next steps. In the ﬁrst study, Dr Iqbal and Dr
Barkataki describe the presentation, care, and outcome of 704
patients, who presented to Gauhati Medical College. The
majority of the patients presented with STEMI (72%), and the
mean delay to presentation was 11 h (10 h for STEMI
patients). Fibrinolytics were used in 39% of the patients with
STEMI and the commonest reason for not getting thrombolytic
therapy was delayed presentation. The 30-day mortality was
just above 10% and pump failure was responsible for about half
of the deaths. Dual anti-platelet therapy (DAPT), and statin use
was nearly universal, while beta-blockers and Angiotensin
converting enzyme inhibitors (ACEI) or angiotensin receptor
blockers (ARB) were used in over 90% of the patients.
The second study describes the results of the Himachal
Pradesh ACS registry. This is a collaborative effort involving 33
hospitals that between them treat over 90% of patients
presenting with ACS in the entire state. In this study, the
proportion of NSTEMI ACS was higher (55%) and overwhelm-
ing majority of patients were rural dwellers (83%). The median
delay to presentation was 13 h and was similar in the STEMI
and NSTEMI patients. Less than a third of patients reached the
hospital within 6 h and ﬁbrinolysis was used in only 36% of
patients with STEMI. The use of DAPT and statins was nearlyuniversal, while the beta blocker and ACEI/ARB use was
somewhat less optimal. The mortality of the STEMI cohort was
approximately 10%.
These studies provide an important insight into the
epidemiology of ACS in India. The most important initial
attempt at understanding ACS in India is represented by the
CREATE registry.1 This registry enrolled 20,937 ACS patients
across 89 centers in 50 cities. STEMI patients comprised the
majority (61%). One of the most noteworthy ﬁnding was that
poor patients did much worse than rich patients (mortality
8.2% vs 5.5%), and this difference was accounted for by
difference in treatment. Rich patients were more likely to
receive thrombolytics (60.6% vs 52.3%), b blockers (58.8% vs
49.6%), lipid-lowering drugs (61.2% vs 36.0%), ACE inhibitors or
ARB (63.2% vs 54.1%), percutaneous coronary intervention
(15.3% vs 2.0%), and coronary artery bypass graft surgery (7.5%
vs 0.7%) compared with poor patients. While the differences in
use of more expensive therapies such as PCI and CABG is
understandable in a predominantly self-pay environment, the
differences in the use of inexpensive pharmacotherapy
suggest that these differences might relate to institutional
factors. It has been previously recognized that care practices
vary at hospitals that provide care to socio-economically
disadvantaged patients and the existence of such clustering
also makes it easier to target quality improvement efforts at
the institutional level.2
The CREATE registry, while exceedingly important, is only a
partial snapshot of ACS in India. It was derived from
predominantly urban tertiary care centers and thus did not
take into account the even more marked heterogeneity in care
across different hospitals in India. Another important mile-
stone in study of ACS in India is the ongoing Kerala ACS
Registry.3 This effort by the Kerala Chapter of the Cardiological
Society of India to study the quality of care and outcomes
associated with ACS included data from 125 of the 185
hospitals in Kerala that provided care to patients with ACS.
These included teaching institutions, private as well as
government hospitals, and a sizeable number of rural
hospitals (40%), thus increasing the generalizability of their
ﬁndings. Fewer than a quarter of the institutions (22%) had a
cardiac catheterization laboratory on site, while 58% had a
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more likely to be younger and to present with ST-elevation
myocardial infarction (STEMI) compared with those in the
registry data from developed countries. The use of lipid-
lowering treatments, beta-blockers, and angiotensin-convert-
ing enzyme inhibitors was low, and few patients had an
invasive approach with coronary revascularization. Throm-
bolytic therapy was underused in STEMI and inappropriately
administered to 19% of patients with non-STEMI and 11% of
those with unstable angina. Not surprisingly, the inappropri-
ate use of thrombolytic therapy was associated with an
increased risk of complications and a trend toward increased
mortality. On the positive side, use of optimal medical therapy
was associated with reduction in mortality and morbidity.4
In this context, what is the added value of the two
publications in the current issue of the journal? Firstly, the
incredible diversity of India means that the challenges of
delivering high quality care are going to be both similar and
different across different regions. Cardiac registries have been
the pioneers of implementation science and extraordinarily
effective at translating the evidence base to evidence-based
practice. The association between better processes of care and
clinical outcome in patients with ACS is well recognized. There
is a strong association between mortality and hospital
adherence to Class I American College of Cardiology (ACC)/
American Heart Association (AHA)-recommended therapies
among patients with non-ST elevation ACS, with a 10% decline
in in-hospital mortality for every 10% increase in adherence to
a composite of nine proven therapeutic strategies.5 Similarly, a
study from Sweden evaluated the trends in treatment and
outcome of patients presenting with STEMI and demonstrated
a remarkable uptake in use of evidence-based therapies and a
parallel decline in early as well as 1-year mortality.6
Quality improvement systems generally evolve as deﬁned
in Fig. 1. The work by Iqbal and Barkataki represents the ﬁrst
two steps in this cycle. The investigators should take the next
step and develop a local network of hospitals that can compare
care processes and assess outcomes across the entire North-
Eastern region. The Himachal ACS registry on the other hand is
now in a position not only to deﬁne the lacunae in care but can
be used also to develop and deliver simple tools that can help
overcome these.Fig. 1 – The evolution ofPrior experience suggests that such efforts can be remark-
ably successful. The 'Guidelines Applied in Practice' project
was a multi-institutional statewide effort in Michigan, USA to
embed the best care practices into a standardized admission
and discharge templates across the participating institutions.
This resulted in an immediate improvement in the utilization
of evidence-based therapy both during hospitalization and
post-discharge along with an associated reduction in mortality
at 30 days and 1 year.7
The need for of optimizing use of evidence-based therapies
and reducing the use of unproven therapies cannot be
overstated. The ﬁrst step in the process of understanding
the gaps in care is collection of data, and this needs to be
followed by measures to critically understand the reasons for
these gaps and to rectify them. This has to be combined with
ongoing audit and data collection, so that the quality
improvement effort can be reshaped to a changing target
(Fig. 2).
As a ﬁrst step the organic growth of studies assessing
processes of care and outcomes of ACS is a welcome sign of
maturity of the Indian healthcare market. As different
registries emerge, it would behoove the national cardiology
leadership to create a national data collection system akin to
the American College of Cardiology lead National Cardiovas-
cular Data registry (NCDR) but with the ability to permit and
even encourage local efforts at data collection and quality
improvement. The strength of the Indian software industry
combined with the natural Juggad entrepreneurship skills and
the experience of the Indian Diaspora create a formula for
success that can match and exceed what has been achieved
elsewhere.
In recognition of the diversity that we Indians love to
celebrate, it would be important to encourage both local and
national registries in parallel and ensure that national
registries foster the growth of local sub-registries. These
regional registries serve as learning networks and this helps
drive quality improvement. The success of the Kerala Registry
was in part related to its local roots and connections that
facilitated close collaboration and made the registry successful
in translating these ﬁndings into actionable goals. In our work
with the Blue Cross Blue Shield of Michigan Cardiovascular
Collaborative (BMC2), I have long recognized the value of health care quality.
Fig. 2 – The quality cycle: a schematic depicting the never ending cycle of quality improvement. High quality data collection is
used to identify gaps in care processes, quality improvement efforts are developed to bridge these gaps, the resultant
improvements in care are quantified, and the lessons learnt are then shared across the network. This is followed by
refinement of quality goals, and the cycle repeats itself.
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of local registries. This permits open sharing of data, facilitates
honest dialog and encourages sharing of best practices with
the ultimate goal of improving patient care. Our registry,
which is focused on improving outcome and appropriateness
of PCI, has successfully reduced variation in practice across
the entire state, reduced average contrast dose, increased
use of appropriate antiplatelet therapy and hydration prior to
the procedure, and demonstrated improvement in clinical
outcomes such as contrast-induced nephropathy, vascular
complications, and post-procedural myocardial infarction.
These efforts have been replicated by others and have
consistently resulted in improved outcomes and cost
savings.8
The natural extension of such registries is the ability to
translate data collection into quality improvement. The use of
such an approach in a resource constrained environment has
been effectively demonstrated by our Brazilian colleagues.
Berwanger and colleagues tested an intensive multifaceted
quality improvement strategy on improving ACS care.9 This
included use of reminders, case management checklists and
tools, and intensive education of clinicians. There was an
increase in use of dual antiplatelet therapy (75% vs. 89%),
statins (73% vs. 83%), and anticoagulant therapy (81% vs. 87%)
during hospitalization, and the overall adherence to all acute
and discharge therapies increased from 32% to 51%. The
lessons from this study can be easily applied across other
middle and low income countries and should be of speciﬁc
interest to Indian investigators.
It is heartening to note that the use of appropriate medical
therapy in the current studies was much better than
historically noted and while exceptional in some centers
could be improved at the others. Optimization of medical carewould be the ﬁrst target for quality improvement, but other
more challenging issues will also need to be tackled.
Two obvious targets that stand out from the current studies
are the need to curb tobacco use and to reduce delay to
presentation among patients with ACS. The use of tobacco
products continues to be a major driver of cardiovascular
disease, and efforts to curb its use might be the most effective
public health measure at preventing ACS.10 The incidence of
myocardial infarction after initiation of antismoking regula-
tions falls quickly, and beneﬁts both smokers and non-
smokers. Although smoking rates have declined in the West,
smoking remains one of the most important risk factors for
STEMI and population strategies targeted at smoking cessa-
tion have been estimated to be especially effective at
preventing myocardial infarction in the young.11 In India,
tobacco use remains widely prevalent, especially among the
young and poorer sections of the society.12 Reduction in
tobacco use will require a combination of policy approaches
with legal restrictions and punitive taxation, effective imple-
mentation of current laws and shift in societal acceptance of
tobacco use to active disapproval. Similarly, better control of
risk factors with improved screening and control of hyperten-
sion and hyperlipidaemia would have major salutary beneﬁts
at reducing the incidence of ACS.
The second and more difﬁcult challenge would be to target
the prolonged delay to presentation among patients with ACS.
While the authors of the Himachal registry did attempt to
study the factors for these delays, this subject needs further
study. It is remarkable that these delays are similar across both
the studies as well as in the Kerala registry. While it would be
premature to ascribe the cause to these, I suspect that
perceived economic barriers and lack of awareness of the
importance of early treatment of ACS play an important role in
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address these issues with strategies that are speciﬁcally
tailored for the local socio-geographic factors.
The key factors responsible for the decline in coronary
mortality in the USA are believed to be improvement in risk
factor proﬁles, and effective primary and secondary treat-
ments of ACS.13 High-tech and expensive therapies such as
revascularization account for only 5% of this improvement in
survival, suggesting that community-wide risk factor control
and wider use of appropriate medical therapy should be
explored as ﬁrst-line strategies to achieve a similar reduction
in coronary mortality in India.
A few years ago I had the privilege to co-author a
commentary on the Kerala ACS registry. We had invoked
the need for a two-pronged quality improvement strategy: the
ﬁrst focused on prevention of ACS and the second on better
treatment and the same approach remains relevant for the
current investigators.14 The Kerala ACS investigators have
been working hard at implementing hospital level change and
are already noticing remarkable change in care and outcome
(Dr Mohanan, Private communication, August 25, 2015). I
remain positive that the current group of investigators will
follow up their work with similar steps and the ongoing use of
data to improve the care of ACS will become a standard part of
clinical care, across these institutions and beyond.
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